Skip to main content
AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.79%KO-0.71%0700.HK-6.57%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.05%ORCL-0.97%3988.HK-0.60%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.91%0857.HK-2.43%UNH-10.21%1288.HK-1.49%PM-0.85%0005.HK-2.10%NVS-2.46%INTC-0.91%HSBA.L-2.00%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.55%AUDUSD-1.47%AUDNZD-0.89%AUDCAD-0.88%EURAUD+0.88%AUDCHF-0.85%GBPAUD+0.82%GBPJPY-0.73%EURJPY-0.70%CHFJPY-0.69%CADJPY-0.68%NZDJPY-0.68%USDCHF+0.64%GBPUSD-0.63%USDCAD+0.60%EURUSD-0.60%NZDUSD-0.58%AUDSGD-0.52%USDZAR+0.45%AUDDKK-0.43%GBPTRY+0.41%USDTHB+0.34%GBPHKD+0.32%AUDNOK-0.32%NZDMXN+0.31%USDMXN+0.30%EURZAR+0.29%GBPMXN-0.28%USDNOK+0.28%GBPZAR+0.27%USDSEK+0.22%USDTRY+0.21%USDPLN+0.21%EURCNH-0.19%CHFNOK+0.19%EURHKD-0.16%USDILS+0.16%USDDKK+0.16%NOKJPY-0.16%CHFSEK+0.13%EURNOK+0.12%USDCNH-0.11%NZDSGD+0.10%USDJPY-0.10%GBPSGD-0.10%EURSGD-0.09%PLNJPY-0.08%USDSGD+0.07%EURSEK+0.07%SGDJPY+0.06%GBPNZD-0.06%GBPCAD-0.06%EURPLN+0.05%EURGBP+0.04%EURCHF+0.04%USDCOP-0.04%EURCZK+0.04%CADCHF+0.04%NZDCHF+0.03%EURNZD-0.03%CHFSGD-0.03%USDHKD-0.01%EURCAD0.00%GBPCHF0.00%EURDKK0.00%NZDCAD0.00%XPTUSD-0.79%XNGUSD-0.60%W1-0.51%C1-0.44%GAGUSD-0.42%XAGUSD-0.42%XAUUSD-0.41%GAUUSD-0.41%UKOIL+0.32%S1-0.26%HG1-0.23%COTTON+0.06%BTCUSD-2.93%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.87%ZECUSDT-5.74%XMRUSDT-1.64%DOGEUSD+55.95%LINKUSD-2.67%XLMUSD-3.27%BCHUSDT-3.03%LTCUSD+47.50%UNIUSD-2.22%SUIUSD-2.19%TONUSD+59.18%HBARUSDT-4.63%TAOUSDT-2.21%AAVEUSD-2.73%ONDOUSDT-4.04%ICPUSDT-1.70%DOTUSDT-3.23%WLDUSDT-2.82%ARBUSDT-5.08%ATOMUSDT-1.71%INJUSDT-6.68%STXUSDT-1.68%PYTHUSDT+0.83%TIAUSDT-2.26%FETUSDT-3.86%JUPUSDT+1.39%SEIUSDT-2.00%GRTUSDT-2.94%OPUSDT-2.63%IOTAUSDT-1.90%POLUSDT-1.51%WIFUSDT-2.25%AXSUSDT-2.18%EOSUSDT-3.74%IMXUSDT-3.36%FARTCOINUSDT-5.88%GALAUSDT-1.65%DYDXUSDT-2.17%ORDIUSDT-1.79%NOTUSDT-0.74%RONINUSDT-2.92%AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.79%KO-0.71%0700.HK-6.57%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.05%ORCL-0.97%3988.HK-0.60%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.91%0857.HK-2.43%UNH-10.21%1288.HK-1.49%PM-0.85%0005.HK-2.10%NVS-2.46%INTC-0.91%HSBA.L-2.00%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.55%AUDUSD-1.47%AUDNZD-0.89%AUDCAD-0.88%EURAUD+0.88%AUDCHF-0.85%GBPAUD+0.82%GBPJPY-0.73%EURJPY-0.70%CHFJPY-0.69%CADJPY-0.68%NZDJPY-0.68%USDCHF+0.64%GBPUSD-0.63%USDCAD+0.60%EURUSD-0.60%NZDUSD-0.58%AUDSGD-0.52%USDZAR+0.45%AUDDKK-0.43%GBPTRY+0.41%USDTHB+0.34%GBPHKD+0.32%AUDNOK-0.32%NZDMXN+0.31%USDMXN+0.30%EURZAR+0.29%GBPMXN-0.28%USDNOK+0.28%GBPZAR+0.27%USDSEK+0.22%USDTRY+0.21%USDPLN+0.21%EURCNH-0.19%CHFNOK+0.19%EURHKD-0.16%USDILS+0.16%USDDKK+0.16%NOKJPY-0.16%CHFSEK+0.13%EURNOK+0.12%USDCNH-0.11%NZDSGD+0.10%USDJPY-0.10%GBPSGD-0.10%EURSGD-0.09%PLNJPY-0.08%USDSGD+0.07%EURSEK+0.07%SGDJPY+0.06%GBPNZD-0.06%GBPCAD-0.06%EURPLN+0.05%EURGBP+0.04%EURCHF+0.04%USDCOP-0.04%EURCZK+0.04%CADCHF+0.04%NZDCHF+0.03%EURNZD-0.03%CHFSGD-0.03%USDHKD-0.01%EURCAD0.00%GBPCHF0.00%EURDKK0.00%NZDCAD0.00%XPTUSD-0.79%XNGUSD-0.60%W1-0.51%C1-0.44%GAGUSD-0.42%XAGUSD-0.42%XAUUSD-0.41%GAUUSD-0.41%UKOIL+0.32%S1-0.26%HG1-0.23%COTTON+0.06%BTCUSD-2.93%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.87%ZECUSDT-5.74%XMRUSDT-1.64%DOGEUSD+55.95%LINKUSD-2.67%XLMUSD-3.27%BCHUSDT-3.03%LTCUSD+47.50%UNIUSD-2.22%SUIUSD-2.19%TONUSD+59.18%HBARUSDT-4.63%TAOUSDT-2.21%AAVEUSD-2.73%ONDOUSDT-4.04%ICPUSDT-1.70%DOTUSDT-3.23%WLDUSDT-2.82%ARBUSDT-5.08%ATOMUSDT-1.71%INJUSDT-6.68%STXUSDT-1.68%PYTHUSDT+0.83%TIAUSDT-2.26%FETUSDT-3.86%JUPUSDT+1.39%SEIUSDT-2.00%GRTUSDT-2.94%OPUSDT-2.63%IOTAUSDT-1.90%POLUSDT-1.51%WIFUSDT-2.25%AXSUSDT-2.18%EOSUSDT-3.74%IMXUSDT-3.36%FARTCOINUSDT-5.88%GALAUSDT-1.65%DYDXUSDT-2.17%ORDIUSDT-1.79%NOTUSDT-0.74%RONINUSDT-2.92%
KT

Kymera Therapeutics, Inc. (KYMR)

NASDAQ • Healthcare

$121.13
-$0.39 (-0.3%)
Market closed

Last close at November 18, 2026 at 21:00 UTC

Open$120.38
Day Range$119.84 - $127.45
Avg. Volume (3M)994.6K
Market Cap$10.3B
52 Week Range
$63.69$142.92

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$102.2M
Net Income (TTM)
-$349.4M
EPS (TTM)
-$3.63
ROA (TTM)
-19.77%
Current Ratio
11.13

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+20.2%Q2 2026-$0.71
+13.0%Q3 2026-$0.62
-4.8%Q4 2026-$1.32

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Miss -4.8%

Kymera Therapeutics’ preliminary results for the third fiscal quarter of 2026, reported October 29, 2026, showed EPS of -$1.32 trailing the -$1.26 estimate by -$0.06 as the company posted a wider year-over-year loss. Net income came in at -about $132.0 million, a -61% change year over year and down from roughly -$82.2 million a year ago, while operating income was -around $147.2 million. The period reflected ongoing spend across its drug discovery and development efforts, including targeted programs such as IRAK4, with no segment-level revenue detail provided in the preliminary release. Operating cash flow was negative at about -$77.9 million, consistent with the company funding R&D and operations. For year-over-year context on per-share results, EPS deteriorated -47% from -$0.90 a year ago. Consensus for the next period calls for EPS of -$1.28 on revenue of $1.2 million.

View full earnings history

About Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. is a NASDAQ-listed biotechnology company that develops small molecule therapeutics designed to harness the body's protein degradation system to eliminate disease-causing proteins. In healthcare, its work centers on drug discovery and development, and it recorded $39.2 million of revenue in FY2025.

Name
Kymera Therapeutics, Inc.
CEO
Nello Mainolfi
Industry
Healthcare
Year Founded
2015
Employees
273

Today's Snapshot

AI-generated

KYMR closed slightly lower at 121.13, while its sector was weaker. Shares changed hands at about two-thirds of its usual level.

Trading Volume

Below 10d avg (923.9K)

646.5K

vs S&P 500 Today

Inline with Market

-0.06%

Updated: November 18, 2026 at 21:14 UTC

Technical Indicators

3 Buy3 Neutral2 Sell
KYMR leans bullish overall as trend measures show modest strength and longer-term moving averages remain well below the current price, indicating underlying support despite near-term weakness. Momentum indicators are mixed with MACD positive yet short-term momentum negative and RSI around neutral, while ATR signals moderate volatility. On-balance volume is currently negative, suggesting recent distributions have not yet overwhelmed the broader uptrend, and the pivot lies just above the market as a nearby reference. Technical takeaway: Buy — longer-term trend intact though short-term pullback and volume warrant caution.
All signals
  • EMA (5 indicators)$100.91 - $126.38
    Buy
  • RSI (14)47.36
    Neutral
  • Stochastic %K (14, 3, 3)23.06
    Neutral
  • MACD Level (12, 26)2.86
    Neutral
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.